Lipoprotein Kinetics in T1D

NCT ID: NCT05179954

Last Updated: 2026-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-09

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Not required

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Cross-sectional comparison (T1D vs healthy control)
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Healthy control group

Group Type OTHER

Metabolic testing

Intervention Type OTHER

Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics

T1D group

T1D group

Group Type ACTIVE_COMPARATOR

Metabolic testing

Intervention Type OTHER

Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metabolic testing

Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: ≥18 but ≤45 years
* premenopausal/eumenorrheic and not pregnant or breastfeeding
* non-obese (body mass index ≥18.5\<30.0 kg/m2)
* Fasting plasma triglyceride \<150 mg/dL


* Fasting plasma glucose \<100 mg/dL
* Plasma glucose 2 h after a 75 g oral glucose challenge \<140 mg/dL
* HbA1c \<5.6%.


* stable insulin regimen (multiple daily insulin injections or continuous subcutaneous insulin) for at least 8 weeks before screening
* no use of diabetes medications other than insulin
* HbA1c \<8.0%, basal (overnight fasted)
* no severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or a medical facility in the 6 months prior to screening or metabolic testing

Exclusion Criteria

* more than 1.5 h of structured exercise/week
* use of tobacco products, excessive amounts of alcohol, or dietary supplements and/or medications known to affect lipid metabolism
* hypothyroidism or other disorders known to affect lipid metabolism
* conditions that would make it impossible to complete the study protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Washington

OTHER

Sponsor Role collaborator

University of Missouri-Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bettina Mittendorfer

Senior Associate Dean for Research

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bettina Mittendorfer

Role: PRINCIPAL_INVESTIGATOR

University of Missouri-Columbia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Missouri School of Medicine

Columbia, Missouri, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amanda Heider

Role: CONTACT

(573) 884-6852

Mittendorfer Lab

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bettina Mittendorfer, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2097324

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Beta Cell Function in (Pre) Type 1 Diabetes
NCT00800085 UNKNOWN PHASE1/PHASE2
Diabetes Type 1 and Fitness.
NCT04968171 RECRUITING